Trial ID: | L0722 |
Source ID: | NCT00472082
|
Associated Drug: |
Efalizumab
|
Title: |
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
|
Acronym: |
|
Status: |
TERMINATED
|
Study Results: |
YES
|
Results: |
https://ClinicalTrials.gov/show/NCT00472082/results
|
Conditions: |
Kidney Transplantation|Chronic Kidney Failure
|
Interventions: |
DRUG: efalizumab
|
Outcome Measures: |
Primary: Efficacy Will be Determined by Change in Renal Function as Measured by Cold Iothalamate Glomerular Filtration Rate(GFR)3 Months After Enrollment, and Acute Rejection Episodes Within the First 6 Months Post Enrollment., 6 months from conversion | Secondary: Safety, Including Incidence of Post- Transplant Infections, Malignancies, Morbidities, Hypertension, Glucose Intolerance, Serum Cholesterol and Triglycerides Profile Over Time, Development of New Anti-donor Antibodies., 1 year
|
Sponsor/Collaborators: |
Sponsor: Emory University | Collaborators: Genentech, Inc.
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE1|PHASE2
|
Enrollment: |
5
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2007-05
|
Completion Date: |
2009-04
|
Results First Posted: |
2012-12-06
|
Last Update Posted: |
2014-01-27
|
Locations: |
Emory University, Atlanta, Georgia, 30322, United States
|
URL: |
https://clinicaltrials.gov/show/NCT00472082
|